The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04202952
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC74647 in HCV-infected Subjects
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04201275
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04194242
- Locations
- 🇨🇳
The Shanghai xuhui district central hospital, Shanghai, Shanghai, China
Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 250
- Registration Number
- NCT04147208
- Locations
- 🇨🇳
Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Beijing YouAn Hospital,Capital Medical University, Beijing, Beijing, China
Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
- First Posted Date
- 2019-10-18
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT04131192
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, China/jiangsu, China
🇨🇳shandong Cancer Hospital, Jinan, China/shandong, China
The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 69
- Registration Number
- NCT03943251
- Locations
- 🇨🇳
The Shanghai xuhui district central hospital, Shanghai, Shanghai, China
The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT03903081
- Locations
- 🇨🇳
The First Hospital of Jilin University, Changchun, Jilin, China
Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2023-03-21
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT03888092
- Locations
- 🇨🇳
Chinese PLA General Hospital, the Fifth Medical Center, Beijing, Beijing, China
HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT03886688
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
A Single Arm, Open-label,Phase Ib Study of CT053PTSA in Preciously Treated Patients With Advanced and Metastatic RCC
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT03876925
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China